The adoption of Wegovy, a {semaglutide-based|GLP-1 agonist medication, in the UK has prompted careful evaluation and the development of clear protocols for its administration. Current official positioning emphasizes that Wegovy is primarily intended for individuals with significant weight concerns, or those with associated health conditions such as